Updated results from a multicenter, phase 2 study of acalabrutinib, venetoclax, obinutuzumab (AVO) in a population of previously untreated patients with CLL enriched for high-risk disease

Acalabrutinib, venetoclax, and obinutuzumab (AVO) was well tolerated in the frontline for those patients with high-risk CLL. Of those with TP53 mutations, 83% had undetectable disease in the bone marrow (BM-uMRD) after 15 months of treatment. At median follow up of 3 years, responses were found to be durable, with 93% progression-free survival in all patients.